International Liver Congress https://www.bioworld.com/rss en-us First-in-class thioacrylamide compound reduces hepatic fibrosis in 3D spheroid MASH model http://www.bioworld.com/articles/709562 Fri, 14 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709562-first-in-class-thioacrylamide-compound-reduces-hepatic-fibrosis-in-3d-spheroid-mash-model Liver over digital lens background JNJ-9117, a potent pan-genotype HEV replication inhibitor with promising antiviral profile http://www.bioworld.com/articles/709393 Wed, 12 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709393-jnj-9117-a-potent-pan-genotype-hev-replication-inhibitor-with-promising-antiviral-profile SA-012 alone or in combination clears HBsAg in murine model N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB).]]> http://www.bioworld.com/articles/709417 Tue, 11 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709417-sa-012-alone-or-in-combination-clears-hbsag-in-murine-model SA-012 alone or in combination clears HBsAg in murine model N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB).]]> http://www.bioworld.com/articles/709366 Tue, 11 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709366-sa-012-alone-or-in-combination-clears-hbsag-in-murine-model AD-66810 siRNA shows antiviral efficacy in preclinical HBV infection model http://www.bioworld.com/articles/709328 Mon, 10 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709328-ad-66810-sirna-shows-antiviral-efficacy-in-preclinical-hbv-infection-model EASL 2024: Epigenetics as door to liver cancer treatment http://www.bioworld.com/articles/709324 Mon, 10 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709324-easl-2024-epigenetics-as-door-to-liver-cancer-treatment Epigenetics concept art. Credit: Darryl Leja, National Human Genome Research Institute, NIH Novel 17β-HSD13 inhibitor reduces fibrosis and steatosis in a MASH model http://www.bioworld.com/articles/709311 Fri, 07 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709311-novel-17-hsd13-inhibitor-reduces-fibrosis-and-steatosis-in-a-mash-model Liver illustration SNORA47 and SNORD126 behind prognosis of nonviral hepatocellular carcinoma http://www.bioworld.com/articles/709303 Fri, 07 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709303-snora47-and-snord126-behind-prognosis-of-nonviral-hepatocellular-carcinoma Photomicrograph of hepatocellular carcinoma Photomicrograph of hepatocellular carcinoma. EASL 2024: Hepatocyte journey across liver disease and beyond http://www.bioworld.com/articles/709295 Fri, 07 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709295-easl-2024-hepatocyte-journey-across-liver-disease-and-beyond Human liver cell. Hepatocytes. Credit: Donna Beer Stolz, University of Pittsburgh/NIH Preclinical antiviral efficacy of BJT-778 reported at EASL http://www.bioworld.com/articles/709182 Wed, 05 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709182-preclinical-antiviral-efficacy-of-bjt-778-reported-at-easl Illustration of liver infection Precision Biosciences novel gene-editing approach may lead to a functional cure for HBV http://www.bioworld.com/articles/709181 Wed, 05 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709181-precision-biosciences-novel-gene-editing-approach-may-lead-to-a-functional-cure-for-hbv